SOURCE: Sirona Biochem Corp.

Sirona Biochem Corp.

March 12, 2015 14:49 ET

Sirona Biochem to Present at BIO Asia 2015 and Received Over $1.1 Million of Warrants Exercised

VANCOUVER, BC--(Marketwired - March 12, 2015) - Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) announces that its Chief Business Development Officer, Attila Hajdu, will be presenting at BIO Asia, March 24-25, 2015 in Tokyo, Japan. The Company's CSO, Dr. Geraldine Deliencourt-Godefroy, will also be attending.

The BIO Asia International Conference, co-hosted by the Biotechnology Industry Organization (BIO), BioCentury and the Japan Bioindustry Association (JBA), brings together the global biotechnology and pharmaceutical industry to explore licensing and research collaborations in the current Asia-Pacific business and policy environments.

The conference is an exclusive, customized partnering forum featuring private, pre-arranged one-on-one meetings between senior-level executives, using BIO's proprietary, state-of-the-art computer software. The format and selective nature of the conference makes this the premier dedicated biotech partnering event in Asia and an unrivaled opportunity to meet with the leading industry organizations in one place at one time.

The conference will provide an international stage for Sirona to present recently publicized results and partnering opportunities to leading pharmaceutical and biotech companies. Representation will include major organizations from both North American and Asia, including: Pfizer, Johnson & Johnson, Amgen, GSK, Daiichi Sankyo, Takeda, Eli Lily and many more. In 2014, nearly 40% of the 130 companies attending were Pharma companies.

Mr. Hajdu and Dr. Deliencourt-Godefroy will also be attending a number of additional meetings outside of the conference with cosmetic companies headquartered in the Tokyo area.

Warrants Exercised

Sirona Biochem is also pleased to announce that it has received $1,186,050 in cash on exercise of 7,907,000 warrants exercised at $0.15 per warrant. Each warrant was exercisable into one common share of the Corporation. The warrants had an expiration date of March 5, 2015. As of today, there are 138,030,490 shares issued and outstanding.

"The company is now in a strong cash position to continue the execution of its business plan and we look forward to announcing our commercialization successes in 2015," commented Howard Verrico, CEO of Sirona Biochem.

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information please visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

Contact Information